Protein O-GlcNAcase
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein homooligomer Homooligomer Protein × 2 PDB declaration: dimeric(2) Consistent with protein copy count | Chain AAA; UniProt 1–916 Chain BBB; UniProt 1–916 | Not recorded | 1XI ~{N}-[(3~{Z},6~{S},7~{R},8~{R},8~{a}~{S})-7,8-bis(oxidanyl)-3-(phenylmethyl)imino-1,5,6,7,8,8~{a}-hexahydro-[1,3]thiazolo[3,4-a]pyridin-6-yl]ethanamide × 2 | X-RAY DIFFRACTION X-ray crystallization conditions:VAPOR DIFFUSION, HANGING DROP;pH 7.5;291.15 K;0.14 - 0.2 M triammonium citrate pH 7.5, 16-20 % PEG 3350 | Resolution 2.41 Å R-free 0.271 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 7OU6 | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 2YDQ CpOGA D298N in complex with hOGA-derived O-GlcNAc peptide Deposited 2011-03-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain T
402–408(7 aa)
Fragment:HOGA O-GLCNAC PEPTIDE, RESIDUES 402-408
|
Not recorded | CD CADMIUM ION × 19 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5;0.6M NAAC, 0.175M CDSO4, 0.1M HEPES PH 7.5
|
Resolution 2.60 Å R-free 0.231 |
| 5M7R Structure of human O-GlcNAc hydrolase Deposited 2016-10-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
1–916(916 aa)
Chain B
1–916(916 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;292 K;0.14 - 0.2 M triammonium citrate pH 7.5, 16-20 % PEG 3350
|
Resolution 2.35 Å R-free 0.249 |
| 5M7S Structure of human O-GlcNAc hydrolase with bound transition state analog ThiametG Deposited 2016-10-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
1–916(916 aa)
Chain B
1–916(916 aa)
|
Not recorded | NHT (3AR,5R,6S,7R,7AR)-2-(ETHYLAMINO)-5-(HYDROXYMETHYL)-5,6,7,7A-TETRAHYDRO-3AH-PYRANO[3,2-D][1,3]THIAZOLE-6,7-DIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;292 K;0.1-0.2 M tri ammonium citrate pH 7.5
16-20 % PEG 3350
|
Resolution 2.40 Å R-free 0.232 |
| 5M7T Structure of human O-GlcNAc hydrolase with PugNAc type inhibitor Deposited 2016-10-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
1–916(916 aa)
Chain B
1–916(916 aa)
|
Not recorded | GDV (5R,6R,7R,8S)-8-(ACETYLAMINO)-6,7-DIHYDROXY-5-(HYDROXYMETHYL)-N-PHENYL-1,5,6,7,8,8A-HEXAHYDROIMIDAZO[1,2-A]PYRIDINE-2-CARBOXAMIDE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;292 K;0.1-0.2 M tri Ammonium citrate 16-20 % PEG 3350
|
Resolution 2.60 Å R-free 0.235 |
| 5M7U Structure of human O-GlcNAc hydrolase with new iminocyclitol type inhibitor Deposited 2016-10-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
1–916(916 aa)
Chain B
1–916(916 aa)
|
Not recorded | XHA 2-[(2~{R},3~{S},4~{R},5~{R})-5-(hydroxymethyl)-3,4-bis(oxidanyl)-1-[3-[3-(trifluoromethyl)phenyl]propyl]pyrrolidin-2-yl]-~{N}-methyl-ethanamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;292 K;0.1-0.2 M tri Ammonium citrate pH 7.5 16-20 % PEG 3350
|
Resolution 2.30 Å R-free 0.227 |
| 5TKE Crystal Structure of Eukaryotic Hydrolase Deposited 2016-10-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
60–400(341 aa)
Fragment:unp residues 60-542; unp residues 553-704
Chain A
553–704(152 aa)
Fragment:unp residues 60-542; unp residues 553-704
Chain B
60–400(341 aa)
Fragment:unp residues 60-542; unp residues 553-704
Chain B
553–704(152 aa)
Fragment:unp residues 60-542; unp residues 553-704
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;pH 7;293 K;0.032 M ammonium citrate tribasic (pH 7.0), 0.02 M MES monohydrate, 0.016 M imidazole, 0.002 M zinc sulfate heptahydrate, 0.128 M potassium thiocyanate, 12.8% w/v polyethylene glycol 3,350, 3.2% w/v polyethylene glycol monomethyl ether 2,000, and 5% w/v polyethylene glycol monomethyl ether 550
|
Resolution 2.48 Å R-free 0.236 |
| 5UHK Crystal structure of the core catalytic domain of Human O-GlcNAcase Deposited 2017-01-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
56–400(345 aa)
Chain B
544–705(162 aa)
Chain C
56–400(345 aa)
Chain D
544–705(162 aa)
|
Not recorded | GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;14-17% PEG 3350, 0.2 M Mg Formate
|
Resolution 2.97 Å R-free 0.251 |
| 5UHL Crystal structure of the core catalytic domain of human O-GlcNAcase complexed with Thiamet G Deposited 2017-01-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
56–400(345 aa)
Chain B
544–705(162 aa)
Chain C
56–400(345 aa)
Chain D
544–705(162 aa)
|
Not recorded | 8BJ (2Z,3aR,5R,6S,7R,7aR)-2-(ethylimino)-5-(hydroxymethyl)hexahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;14-17% PEG 3350, 0.2 M Mg Formate
|
Resolution 3.14 Å R-free 0.257 |
| 5UHO Crystal structure of the core catalytic domain of human O-GlcNAcase complexed with PUGNAc Deposited 2017-01-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
56–400(345 aa)
Chain B
544–705(162 aa)
Chain C
56–400(345 aa)
Chain D
544–705(162 aa)
|
Not recorded | OAN O-(2-ACETAMIDO-2-DEOXY D-GLUCOPYRANOSYLIDENE) AMINO-N-PHENYLCARBAMATE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;14-17% PEG 3350, 0.2 M Mg Formate
|
Resolution 3.21 Å R-free 0.259 |
| 5UHP Crystal structure of the core catalytic domain of human O-GlcNAcase Deposited 2017-01-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
14–400(387 aa)
Chain B
14–400(387 aa)
Chain F
554–705(152 aa)
Chain G
554–705(152 aa)
|
Not recorded | GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M K Na tartrate tetrahydrate, 20% PEG 3350
|
Resolution 2.79 Å R-free 0.292 |
| 5UHP Crystal structure of the core catalytic domain of human O-GlcNAcase Deposited 2017-01-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain C
14–400(387 aa)
Chain D
14–400(387 aa)
Chain E
554–705(152 aa)
Chain H
554–705(152 aa)
|
Not recorded | GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M K Na tartrate tetrahydrate, 20% PEG 3350
|
Resolution 2.79 Å R-free 0.292 |
| 5UN8 Crystal Structure of human O-GlcNAcase in complex with glycopeptide p53 Deposited 2017-01-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
60–400(341 aa)
Fragment:UNP residues 60-400 and 553-704
Chain A
553–704(152 aa)
Fragment:UNP residues 60-400 and 553-704
Chain C
60–400(341 aa)
Fragment:UNP residues 60-400 and 553-704
Chain C
553–704(152 aa)
Fragment:UNP residues 60-400 and 553-704
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;293 K;0.032 M ammonium citrate tribasic (pH 7.0), 0.02 M MES monohydrate, 0.016 M imidazole, 0.002 M zinc sulfate heptahydrate, 0.128 M potassium thiocyanate, 12.8% w/v polyethylene glycol 3,350, 3.2% w/v polyethylene glycol monomethyl ether 2,000, and 5% w/v polyethylene glycol monomethyl ether 550.
|
Resolution 2.13 Å R-free 0.229 |
| 5UN8 Crystal Structure of human O-GlcNAcase in complex with glycopeptide p53 Deposited 2017-01-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain B
60–400(341 aa)
Fragment:UNP residues 60-400 and 553-704
Chain B
553–704(152 aa)
Fragment:UNP residues 60-400 and 553-704
Chain D
60–400(341 aa)
Fragment:UNP residues 60-400 and 553-704
Chain D
553–704(152 aa)
Fragment:UNP residues 60-400 and 553-704
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;293 K;0.032 M ammonium citrate tribasic (pH 7.0), 0.02 M MES monohydrate, 0.016 M imidazole, 0.002 M zinc sulfate heptahydrate, 0.128 M potassium thiocyanate, 12.8% w/v polyethylene glycol 3,350, 3.2% w/v polyethylene glycol monomethyl ether 2,000, and 5% w/v polyethylene glycol monomethyl ether 550.
|
Resolution 2.13 Å R-free 0.229 |
| 5UN9 The crystal structure of human O-GlcNAcase in complex with Thiamet-G Deposited 2017-01-30 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
60–400(341 aa)
Fragment:UNP residues 60-400 and 553-704
Chain A
553–704(152 aa)
Fragment:UNP residues 60-400 and 553-704
Chain B
60–400(341 aa)
Fragment:UNP residues 60-400 and 553-704
Chain B
553–704(152 aa)
Fragment:UNP residues 60-400 and 553-704
|
Not recorded | NHT (3AR,5R,6S,7R,7AR)-2-(ETHYLAMINO)-5-(HYDROXYMETHYL)-5,6,7,7A-TETRAHYDRO-3AH-PYRANO[3,2-D][1,3]THIAZOLE-6,7-DIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;293 K;0.128 M potassium thiocyanate, 0.032 M ammonium citrate tribasic (pH 7.0), 0.016 M imidazole (pH 7.0), 0.002 M zinc sulfate heptahydrate, 0.02 M MES monohydrate (pH 6.5), 12.8% w/v polyethylene glycol 3,350, 3.2% w/v polyethylene glycol monomethyl ether 2,000, 5% v/v polyethylene glycol monomethyl ether 550
|
Resolution 2.50 Å R-free 0.260 |
| 5VVO Structural Investigations of the Substrate Specificity of Human O-GlcNAcase Deposited 2017-05-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
60–400(341 aa)
Fragment:UNP residues 60-400, 553-704
Chain A
553–704(152 aa)
Fragment:UNP residues 60-400, 553-704
Chain B
60–400(341 aa)
Fragment:UNP residues 60-400, 553-704
Chain B
553–704(152 aa)
Fragment:UNP residues 60-400, 553-704
|
Mutation:D175N Mutation:D175N Mutation:D175N Mutation:D175N | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;293 K;0.024 M ammonium citrate tribasic (pH 7.0), 0.015 M MES monohydrate, 0.096 M potassium thiocyanate, 0.25 M Sodium acetate trihydrate, 0.037 M imidazole, 0.002 M zinc sulfate heptahydrate, 9.6 % w/v polyethylene glycol 3,350, 2.4 % w/v polyethylene glycol monomethyl ether 2,000, and 4% w/v polyethylene glycol monomethyl ether 550
|
Resolution 2.60 Å R-free 0.259 |
| 5VVT Structural Investigations of the Substrate Specificity of Human O-GlcNAcase Deposited 2017-05-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
60–400(341 aa)
Chain A
553–704(152 aa)
Chain C
60–400(341 aa)
Chain C
553–704(152 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;293 K;0.024 M ammonium citrate tribasic (pH 7.0), 0.015 M MES monohydrate, 0.096 M potassium thiocyanate, 0.25 M Sodium acetate trihydrate, 0.037 M imidazole, 0.002 M zinc sulfate heptahydrate, 9.6 % w/v polyethylene glycol 3,350, 2.4 % w/v polyethylene glycol monomethyl ether 2,000, and 4% w/v polyethylene glycol monomethyl ether 550
|
Resolution 2.80 Å R-free 0.291 |
| 5VVU Structural Investigations of the Substrate Specificity of Human O-GlcNAcase Deposited 2017-05-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
60–400(341 aa)
Fragment:UNP residues 60-400, 553-704
Chain A
553–704(152 aa)
Fragment:UNP residues 60-400, 553-704
Chain C
60–400(341 aa)
Fragment:UNP residues 60-400, 553-704
Chain C
553–704(152 aa)
Fragment:UNP residues 60-400, 553-704
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;293 K;0.024 M ammonium citrate tribasic (pH 7.0), 0.015 M MES monohydrate, 0.096 M potassium thiocyanate, 0.25 M Sodium acetate trihydrate, 0.037 M imidazole, 0.002 M zinc sulfate heptahydrate, 9.6 % w/v polyethylene glycol 3,350, 2.4 % w/v polyethylene glycol monomethyl ether 2,000, and 4% w/v polyethylene glycol monomethyl ether 550
|
Resolution 2.70 Å R-free 0.275 |
| 5VVV Structural Investigations of the Substrate Specificity of Human O-GlcNAcase Deposited 2017-05-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
60–400(341 aa)
Fragment:UNP residues 60-400, 553-704
Chain A
553–704(152 aa)
Fragment:UNP residues 60-400, 553-704
Chain C
60–400(341 aa)
Fragment:UNP residues 60-400, 553-704
Chain C
553–704(152 aa)
Fragment:UNP residues 60-400, 553-704
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;293 K;0.024 M ammonium citrate tribasic (pH 7.0), 0.015 M MES monohydrate, 0.096 M potassium thiocyanate, 0.25 M Sodium acetate trihydrate, 0.037 M imidazole, 0.002 M zinc sulfate heptahydrate, 9.6 % w/v polyethylene glycol 3,350, 2.4 % w/v polyethylene glycol monomethyl ether 2,000, and 4% w/v polyethylene glycol monomethyl ether 550
|
Resolution 2.80 Å R-free 0.257 |
| 5VVX Structural Investigations of the Substrate Specificity of Human O-GlcNAcase Deposited 2017-05-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
60–400(341 aa)
Fragment:UNP residues 60-400, 553-704
Chain A
553–704(152 aa)
Fragment:UNP residues 60-400, 553-704
Chain C
60–400(341 aa)
Fragment:UNP residues 60-400, 553-704
Chain C
553–704(152 aa)
Fragment:UNP residues 60-400, 553-704
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;293 K;0.024 M ammonium citrate tribasic (pH 7.0), 0.015 M MES monohydrate, 0.096 M potassium thiocyanate, 0.25 M Sodium acetate trihydrate, 0.037 M imidazole, 0.002 M zinc sulfate heptahydrate, 9.6 % w/v polyethylene glycol 3,350, 2.4 % w/v polyethylene glycol monomethyl ether 2,000, and 4% w/v polyethylene glycol monomethyl ether 550
|
Resolution 2.90 Å R-free 0.282 |
| 6HKI Crystal structure of surface entropy mutant of human O-GlcNAc hydrolase Deposited 2018-09-06 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
1–916(916 aa)
Chain B
1–916(916 aa)
|
Mutation:E602A, E605A Mutation:E602A, E605A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;0.2 M sodium citrate tribasic, 17% polyethylene glycol 3350
|
Resolution 3.30 Å R-free 0.234 |
| 6PM9 Crystal structure of the core catalytic domain of human O-GlcNAcase bound to MK-8719 Deposited 2019-07-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
14–400(387 aa)
Chain B
14–400(387 aa)
Chain F
554–705(152 aa)
Chain G
554–705(152 aa)
|
Not recorded | OQ1 (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M K-Na-tartrate tetrahydrate, 20% (w/v) PEG 3350
|
Resolution 2.86 Å R-free 0.309 |
| 6PM9 Crystal structure of the core catalytic domain of human O-GlcNAcase bound to MK-8719 Deposited 2019-07-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain C
14–400(387 aa)
Chain D
14–400(387 aa)
Chain E
554–705(152 aa)
Chain H
554–705(152 aa)
|
Not recorded | OQ1 (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M K-Na-tartrate tetrahydrate, 20% (w/v) PEG 3350
|
Resolution 2.86 Å R-free 0.309 |
| 7YEH Cryo-EM structure of human OGT-OGA complex Deposited 2022-07-05 | Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain C
1–916(916 aa)
Chain D
1–916(916 aa)
|
Not recorded | UDP URIDINE-5'-DIPHOSPHATE × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.92 Å |
| 8P0L Crystal structure of human O-GlcNAcase in complex with an S-linked CKII peptide Deposited 2023-05-10 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
1–916(916 aa)
Chain B
1–916(916 aa)
|
Not recorded | CYS CYSTEINE × 1 SER SERINE × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291.15 K;0.14 - 0.2 M triammonium citrate pH 7.5, 16-20 % PEG 3350
|
Resolution 2.50 Å R-free 0.271 |
| 9BA8 O-GlcNAcase (OGA) inhibitor complex for the Treatment of Alzheimer's Disease Deposited 2024-04-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
55–713(659 aa)
Chain B
55–713(659 aa)
|
Not recorded | A1AKM N-[4-fluoro-5-({(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl}methyl)-1,3-thiazol-2-yl]acetamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;294 K;15% PEG 3350, 200mM Magnesium Chloride, 100mM Hepes pH 7.0, 5% DMSO
|
Resolution 2.54 Å R-free 0.231 |
| 9BA9 O-GlcNAcase (OGA) inhibitor complex for the Treatment of Alzheimer's Disease Deposited 2024-04-03 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
55–713(659 aa)
|
Not recorded | A1AKL N-{5-[(piperidin-1-yl)methyl]-1,3-thiazol-2-yl}acetamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;281 K;33% PEG 300, 100mM Hepes pH 8.5
|
Resolution 2.75 Å R-free 0.260 |
| 9NE2 cryoEM structure of the human OGA-L Catalytic Dimer Deposited 2025-02-19 | Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
1–916(916 aa)
Chain B
1–916(916 aa)
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.63 Å |
| 9NE4 cryoEM structure of the A-chain of the human OGA-L Catalytic Dimer Deposited 2025-02-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
1–916(916 aa)
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.98 Å |
| 9NE5 cryoEM structure of the B-chain of the human OGA-L Catalytic Dimer Deposited 2025-02-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
1–916(916 aa)
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.05 Å |
| 9QEN Cryo-EM structure of human O-GlcNAcase Deposited 2025-03-10 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
11–420(410 aa)
Chain A
553–916(364 aa)
Chain B
11–420(410 aa)
Chain B
553–916(364 aa)
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.08 Å |
27 other PDB entries and 30 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | OGA_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain AAA; PDBConstruct 1–916; UniProt 1–916 Author chain BBB; PDBConstruct 1–916; UniProt 1–916 |